Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insider Trading Spectrum: From Small-Scale Buddies To “Most Lucrative Inside Tip Of All Time”

Executive Summary

SEC was able to trace trading patterns and relationships between former high school friends back to employees at Celgene and Sanofi; SEC also filed a complaint against a former hedge fund manager who made a record $276 million profit trading on insider information about Alzheimer’s disease drug bapineuzumab.

You may also be interested in...



Pharma-Related Probes Could Be Impacted By Departure Of US Attorneys

Ongoing cases led by New York's Preet Bharara and other US attorneys are unlikely to be affected though their successors could focus on different areas; Boston US Attorney Carmen Ortiz resigned in December.

Insider Trading: Pharma Employees Increasingly In SEC Crosshairs

In past month, three individuals in biopharma space have been charged with insider trading despite efforts by companies and associations to protect confidential information; past sentencing suggests length of jail time former FDA official Gordon Johnston is likely to face.

Beyond Bapi: Alzheimer’s Pipeline Runs Deep

With the failure of the second of four Janssen-led Phase III trials testing bapineuzumab, partners Janssen and Pfizer have elected to discontinue the bapineuzumab I.V. clinical development program. Nonetheless, the anti-amyloid-beta approach is still alive, as the field turns to early, pre-symptomatic intervention.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel